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Abstract 
In this study we report the antimicrobial planktonic and biofilm kill kinetics of ultrashort cationic 
lipopeptides previously demonstrated by our group to have a minimum biofilm eradication 
concentration (MBEC) in the microgram per mL (µg/mL) range against clinically relevant 
biofilm forming microorganisms. We compare the rate of kill for the most potent of these 
lipopeptides, dodecanoic (lauric) acid conjugated C12-Orn-Orn-Trp-Trp-NH2 against the 
tetrapeptide amide H-Orn-Orn-Trp-Trp-NH2 motif and the amphibian peptide Maximin-4 via a 
modification of the MBEC Assay™ for Physiology & Genetics (P&G). Improved antimicrobial 
activity is achieved upon N-terminal lipidation of the tetrapeptide amide. Increased antimicrobial 
potency was demonstrated against both planktonic and biofilm forms of Gram-positive 
microorganisms. We hypothesize rapid kill to be achieved by targeting of microbial membranes. 
Complete kill against established 24 hour Gram-positive biofilms occurred within 4 hours of 
exposure to C12-OOWW-NH2 at MBEC values [methicillin-resistant Staphylococcus 
epidermidis (ATCC 35984): 15.63µg/mL] close to the values for the planktonic minimum 
inhibitory concentration (MIC) [methicillin-resistant Staphylococcus epidermidis (ATCC 
35984): 1.95 µg/mL]. Such rapid kill, especially against sessile biofilm forms, is indicative of a 
reduction in the likelihood of resistant strains developing with the potential for quicker resolution 
of pathogenic infection. Ultrashort antimicrobial lipopeptides have high potential as 
antimicrobial therapy.  
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Introduction 
Cationic antimicrobial peptides exist throughout nature as defense mechanisms in both 
prokaryotic and eukaryotic organisms.  Antimicrobial peptides have evolved over millennia to 
become inherent antimicrobial molecules and effective mediators of the innate and adaptive 
immune response (1). They have been proven to be effective at neutralizing Gram-negative 
bacterial lipopolysaccharide endotoxin and aid the process of wound healing (2,3). Varying in 
the length of their primary sequence, frequently ranging from 12 to 100 amino acids cationic 
variants possess an overall charge between +2 and +9. Cationic antimicrobial peptides display a 
reduced risk of developing resistance due to their multiple modes of action. These include 
targeting of both negatively charged bacterial membranes and intracellular processes including: 
mRNA and protein synthesis; DNA replication and protein folding (4,5). They show preferential 
binding for the negatively charged phospholipid bilayer of bacterial cells compared with 
mammalian membranes which are neutral due to the large presence of sterols, ergosterol (in 
fungi) and cholesterol (in mammalian cells) (4). 
 
Amphibians represent one of the most studied sources of antimicrobial peptides in nature. 
Present in amphibian skin secretions at high concentrations, structural elucidation has made it is 
possible to determine their structure for synthesis in the laboratory via solid phase peptide 
synthesis (6). Lai and colleagues demonstrated that the frog species Bombina maxima produced a 
group of basic peptides, called Maximins, which possessed minimum inhibitory concentrations 
(MIC) in the µg/mL range against a broad spectrum of Gram-positive and -negative bacteria. The 
most potent of these, Maximin-4, consists of twenty seven amino acids 
(GIGGVLLSAGKAALKGLAKVLAEKYAN) with an MIC of 2.7µg/mL against 
Staphylococcus aureus (S.aureus) (7). 
 
Of particular interest in modern healthcare is the development of cost-effective ultrashort 
cationic lipopeptides by rational design of the peptide motif. This involves application of 
structural activity relationships whereby an optimum hydrophobic: charge balance is achieved 
via sequential conjugation of saturated fatty acids to a minimum peptide pharmacophore 
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composed of basic amino acids such as lysine, arginine or histidine (8). The presence of 
hydrophobic amino acids and conjugated fatty acids allows lipopeptides to form an amphipathic 
structure upon interaction with microbial membranes accounting for their detergent-like 
properties (9). Ultrashort peptides by definition consist of a maximum of seven amino acid 
moieties within the primary amino acid sequence (10). Larger molecular weight lipopeptides 
already exist as licensed therapeutics, including polymyxin B, polymyxin E (colistin) and 
daptomycin. Lipopeptides themselves are also produced naturally by bacteria and fungi to 
provide competitive advantage against competing microbes (11). The prospect exists of tailoring 
the amino acid and lipophilic structure to vary the spectrum of activity and selectivity of these 
ultrashort lipopeptides within a minimum structural motif.     
 
Previous results from our group showed that conjugation of dodecanoic acid (C12) to the 
tetrapeptide amide motif amide H-OOWW-NH2, described previously by Bisht and colleagues 
(12), displayed potent biofilm eradication properties in the µg/mL range, with a MBEC value as 
low as 15.63 µg/mL against 24 hour biofilms of methicillin-resistant Staphylococcus epidermidis 
(MRSE) (ATCC 35984) (13). Increased selection for biofilm cells relative to mammalian cells 
was displayed over similar concentration range in vitro. We were also able to incorporate these 
ultrashort cationic peptides and the amphibian antimicrobial peptide Maximin-4 into poly(2-
hydroxyethyl methacrylate) hydrogels for potential use in the prevention of biomaterial 
associated infections (14). These results show promise at a time when modern medicine and 
society are facing an increasing prevalence of resistant hospital and community acquired 
infections and a proportionate slowing in the development of innovative antimicrobial 
compounds (15). Increasing rates of resistant infection can be attributed partly to the ability of 
pathogens to form biofilms: a thick, extracellular polymeric matrix that surrounds microbial cells 
when attached to surfaces, such as indwelling medical devices. The biofilm matrix protects 
microbial cells from antimicrobial attack and provides an optimum environment for survival 
(16). For antimicrobial treatment strategies to be successful they must take into account the 
presence of more resistant, sessile biofilm forms of microorganisms. Targeting of biofilms is 
essential to ensure complete resolution of infection.  
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Our study demonstrates kill kinetics against more resistant biofilm forms of microorganisms, the 
representative phenotype over 80% of clinical infections (17). We describe the implementation 
of a modified MBEC Assay™ to obtain biofilm kill kinetic profiles for the tetrapeptide H-Orn-
Orn-Trp-Trp-NH2. Improved potency was obtained via the conjugation of dodecanoic acid at the 
ornithine terminus with comparison made to results for planktonic time kill studies. Ultrashort 
cationic lipopeptides display a similar spectrum of activity against microbial biofilms as 
naturally occurring antimicrobial peptides, but with a reduced primary sequence, cost and ease of 
synthesis.   
 
Methods  
Materials 
Rink amide 4-(2’,4’-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-MHBA (MBHA) 
resin, all 9-fluorenylmethoxy carbonyl (Fmoc) L-amino acids and 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were obtained from Merck Chemicals 
Ltd (Nottingham, UK). Dodecanoic (lauric) acid was obtained from Sigma-Aldrich (Dorset, 
UK). All other reagents/solvents were peptide synthesis grade. 
 
Peptide synthesis   
Peptides were synthesized using standard 9-fluorenylmethoxy carbonyl (Fmoc) solid phase 
protocols on Rink Amide MHBA resin, using a CEM Liberty (Buckingham, UK) microwave 
enhanced automated peptide synthesizer as previously described (13).  
 
Strains and growth conditions   
The following strains were used in this study: MRSE (ATCC 35984), S.aureus (ATCC 29213), 
methicillin-resistant Staphylococcus aureus (MRSA) (ATCC 43300), Pseudomonas aeruginosa 
(P.aeruginosa) (PA01), Escherichia coli (E.coli) (NCTC 8196), and Candida tropicalis 
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(C.tropicalis) (NCTC 7393). All microbial strains were stored at -70 °C in Microbank vials (Pro-
Lab Diagnostics, Cheshire, UK) and subcultured in Müller Hinton Broth (MHB) before testing. 
 
Universal neutralizer formulation 
A stock solution of universal neutralizer was formed as demonstrated by Booth and colleagues 
(2013) (18). This stock solution was stored as aliquots in sterile eppendorfs and frozen at -20ºC 
until required. 500μl of the universal neutralizer was added to 20mLs of 0.9% sodium chloride 
solution for use in universal inhibitor dilution plates. 
 
Planktonic Kill Kinetics  
The ability of the peptides to kill the planktonic form of MRSE (ATCC 35984), S.aureus (ATCC 
29213), MRSA (ATCC 43300), Pseudomonas aeruginosa (PAO1), E.coli (NCTC 8196) and 
C.tropicalis (NCTC 7393) were evaluated according to CLSI guidelines (19). Peptides were 
selected for kinetic evaluation at the minimum bactericidal (MBC) or minimum fungicidal 
(MFC) concentration previously determined (13). This provided valid analysis of the kill kinetics 
of each antimicrobial as demonstrated by Stratton and colleagues (20). Time points selected to 
assess planktonic kill kinetics were 10 minutes (0.1667 hours), 1, 1.5, 2, 4, 6 and 24 hours with 
quenching of antimicrobial achieved by formulation of a universal neutralizer.   
 
Biofilm Kill Kinetics  
Biofilm rate of kill assays were performed using the Calgary Biofilm Device (MBEC Assay™ 
P&G)(Innovotech Inc., Alberta, Canada), as previously described (21,22). After incubation, 
mature 24 hour biofilm of each susceptible microorganism was challenged with the MBEC value 
and 200µg/mL of peptide (if the MBEC value was equal to or lower than 1000µg/mL). No 
activity corresponds to MBEC value greater than 1000µg/mL, outside the tested concentration 
range from the results obtained previously by our group (13). A 200µg/mL variable was used to 
assess how the same concentration would affect the kill kinetics against different 
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microorganisms. Time points selected for kinetic biofilm eradication assessment were 0.5, 1, 1.5, 
2, 3, 4, 6 and 24 hours. At each of these time points 5 pegs were removed, using sterile flamed 
pliers, from the MBEC lid corresponding to challenged biofilm and a further 5 pegs 
corresponding to positive controls (phosphate buffered saline [PBS]) for the biofilm and placed 
into separate wells of a dilution plates containing universal neutralizer. These were serially 
diluted for subsequent plating on Müeller-Hinton agar to obtain Miles and Misra viable counts 
for each timepoint. 
 
Statistical Analysis  
Statistical analyses were carried out using Microsoft Excel 2010 and GraphPad InStat 3. 
Standard deviations were obtained for viable counts at each concentration of antimicrobial tested 
based on 5 replicates for biofilm counts over 24 hours exposure to varying concentrations 
(µg/mL) of ultrashort antimicrobial lipopeptides and five replicates for rate of kill assays. The 
influence of peptides studied on rate of biofilm eradication (biofilm viable count (Log10 
CFU/peg) at each time point) and their effect on the planktonic rate of kill (Log10 planktonic 
viable counts (Log10 CFU/mL)) were examined using a one way ANOVA, with a Tukey-Kramer 
multiple comparisons test used to identify individual differences relative to the positive control 
(PBS) for each peptide at each timepoint. In all cases a probability of p ≤ 0.05 denoted 
significance. 
 
Results and Discussion 
Cationic antimicrobial peptides and particularly the lipopeptide varieties are of huge importance 
in combating resistance to standard antibiotics as they act rapidly to fully eradicate biofilm, 
unlike some standardly employed antimicrobial regimens (23). Against the less resistant 
planktonic phenotype rapid bactericidal action for all peptides was achieved against all microbial 
isolates (Figures 1-6) within 4 hours at respective MBC or MFCs. Activity was particularly rapid 
against Gram-positive bacterial isolates with 100% kill for the ultrashort lipopeptide C12-
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OOWW-NH2 obtained within 1 hour for MRSE (ATCC 35984), S.aureus (ATCC 29213) and 
MRSA (ATCC 43300).   
 
Increased tolerance to antimicrobial peptides is displayed by the biofilm phenotype compared to 
the planktonic forms due to the presence of an exopolysaccharide matrix with the ability to 
physically slow the diffusion of antimicrobials through the biofilm (24). Nevertheless the 
peptides tested showed rapid action against a range of biofilm cells, with the potential for 
resistance development against lipopeptides in particular, reduced due to complete biofilm kill at 
low exposure times. Complete eradication (5.55 Log10 CFU/peg reduction, P<0.001) of 24 hour 
established biofilms of MRSE (ATCC 35984) at the MBEC (15.63µg/ml) of C12-OOWW-NH2 
was achieved within 4 hours (Figure 7). An increase of almost thirteen times this concentration 
(from 15.63µg/ml to 200µg/ml) resulted in a significant reduction within 1 hour (4.9 Log10 
CFU/peg, P<0.001) and complete eradication within 2 hours, thus demonstrating the dose-
dependent activity of these peptides. The significant (P<0.001) rapid reduction in microbial 
viability demonstrated by C12-OOWW-NH2 and Maximin-4 against planktonic and biofilm 
phenotypes of MRSE within 1 hour, utilizing our kill kinetics model, correlates with a significant 
reduction in the adherence of MRSE within 1 hour using our in vitro biomaterial model with 
these peptides (14). These results are also replicated for C12-OOWW-NH2 when tested against 
all Gram-positive bacteria tested (methicillin sensitive and resistant S.aureus, Figures 8 and 9 
respectively). Kill kinetics were improved compared with non-lipidated H-OOWW-NH2. 
Previous work by Smith and colleagues demonstrated that the licensed antimicrobials 
clindamycin, daptomycin, linezolid, tigecycline and vancomycin were unable to completely kill 
biofilms of MRSA with mean cell survival in treated biofilms of 62%, 4%, 45%, 43% and 19% 
respectively after 24 hours using an XTT assay (22). Therefore the rapid rate of biofilm kill 
achieved by C12-OOWW-NH2 is even more significant when compared with the activity of 
antibacterials such as linezolid and vancomycin, which are reserved for cases of more resistant 
infections (25).  
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Biofilms of Pseudomonas aeruginosa did not exhibit complete eradication in the presence of any 
of the peptides/lipopeptides tested within 24 hours; up to a concentration of 1000µg/ml. 
Therefore kill kinetic analyses were not performed on the biofilm phenotype. E.coli biofilms 
(Figure 10) were only completely eradicated within 24 hours by C12-OOOWW-NH2 at a 
concentration of 500µg/ml (a thirty two fold increase in MBEC compared with MRSE and an 
eight fold increase compared with MRSA). Significant reduction (3 Log10 CFU/peg reduction, 
P<0.001) was achieved within 1 hour exposure to the higher 500µg/ml MBEC value.  Fungal 
C.tropicalis biofilms (Figure 11) were eradicated by C12-OOWW-NH2 within 24 hours at 
concentrations of 250µg/ml (MBEC), however significant reduction (P<0.001) in viable biofilm 
was achieved at both 200µg/ml (3.59 Log10 CFU/peg reduction) and 250µg/ml (3.83 Log10 
CFU/peg reduction) within 4 hours exposure. Biofilm eradication occurs within 24 hours at 
MBEC for C12-OOWW-NH2 against E.coli (NCTC 8196) and C.tropicalis (NCTC 7393) with 
reduced kill kinetics. C12-OOOWW-NH2 displayed a broader range of antimicrobial activity than 
the amphibian-derived peptide Maximin-4 and with the added benefit of reduced synthesis costs 
and relative ease of synthetic manufacture.   
 
Despite the differences in antimicrobial potencies demonstrated by the ultrashort cationic 
peptides and Maximin-4 they share similar antimicrobial activity with regard to their mechanism 
of action  Targeting of microbial membranes is likely to account for the rapid bactericidal and 
biofilm eradication obtained in this report. These cationic peptides bind preferentially to the 
phospholipid bilayer of bacterial cells, which has an overall negative charge compared to neutral 
mammalian cells (26) due to the presence of acidic hydroxylated phospholipids, such as 
phosphatidylglycerol, cardiolipin and phosphatidylserine in the latter (4). Additional acidic 
polymers, such as teichoic acids specific to Gram-positive bacteria (27) and phosphate groups 
present on lipopolysaccharides in Gram-negative bacteria (28), aid in the initial attachment of the 
peptide. This is prior to the formation of transmembrane pores, resulting in self-promoted uptake 
and membrane permeabilization via the toroidal pore, aggregate, barrel stave, and carpet models 
(9). Cationic antimicrobial peptides possess both hydrophobic and hydrophilic amino acid 
residues that allow disruption of bacterial membranes. Improved kill kinetics and reduced MBCs, 
MFC and MBECs are achieved for C12-OOOWW-NH2 relative to non-lipidated H-OOWW-NH2 
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and Maximin-4 as this primary structure has the most optimal hydrophobic: hydrophilic balance, 
thus ensuring increased interaction with microbial membranes and maximal antimicrobial 
activity (9,13). As previously reported by our group haemolysis and cell cytotoxicity studies 
indicated that lipopeptides based on the Cn-OOWW-NH2 motif (where Cn represents the number 
of carbons on the terminal acyl grouping) displayed reduced mammalian cell cytotoxicity and 
increased selectivity for microbial membranes, via comparison with respective MBEC values. 
They have the potential to be safely used within the MIC values for all microorganisms tested 
(13).  
 
Binding of the positively charged peptides to negatively charged biofilm polymeric materials of 
Gram-negative bacteria may retard the penetration of these antimicrobial peptides through the 
biofilm, thus explaining a relative lack of activity against Pseudomonas aeruginosa and E.coli 
biofilms. This effect has been described previously in relation to positively charged 
aminoglycosides and Pseudomonas biofilms (16) and the antiseptic, chlorhexidine and oral 
biofilms (29). The activity of cationic antimicrobial peptides are also affected by the Gram-
negative PhoP/PhoQ regulon and the PmrA/PmrB system, that result in the addition of 
aminoarabinose to lipid A present in the outer membrane of Gram-negative bacteria. This creates 
a membrane with increased cationicity and greater resistance to cationic antimicrobial peptides 
(30). However, membrane disruption may allow synergism with a standard antimicrobial that 
targets microbial cell metabolism, for example rifampicin, which can enter the cell in higher 
quantities to exert its antimicrobial effect. The self-promoted uptake model provides an 
explanation as to why in Gram-negative bacteria many cationic antimicrobial peptides act in 
synergy with conventional antibiotics (31). This strategy may serve as a viable resolution for 
improving the activity of the C12-OOOWW-NH2 in Gram-negative biofilms which proved 
difficult to eradicate fully in our investigations. Synergy of cationic antimicrobial peptides with 
standard antibiotics is not limited to just Gram-negative bacteria but has been proven for both 
Gram-positive bacteria (32) and fungi (33). Clinically such a strategy has been employed 
successfully with the use of the licensed lipopeptide colistin. Combination therapy with 
tobramycin has shown to be superior to single antibiotic monotherapy with the same drugs in the 
treatment of cystic fibrosis patients infected with Pseudomonas aeruginosa (34). The use of 
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ultrashort lipopeptides may serve as a viable alternative to colistin and other standardly used 
antimicrobials for a range of biofilm related infections, with extensive in vivo analysis and 
pharmaceutical formulation studies of C12-OOOWW-NH2 required to study its true clinical 
potential.  
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Fig. 1 Log10 planktonic viable counts (Log10CFU/mL) of MRSE (ATCC 35984) over a period of 
24 hour exposure to the respective MBC value (µg/mL) of H-OOWW-NH2, C12-OOWW-NH2 
and Maximin-4 based on five replicates. 
Key: 
 
NS: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant 
difference between Log10CFU/mL of peptide and the positive control at the same time point 
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Fig. 2 Log10 planktonic viable counts (Log10CFU/mL) of S.aureus (ATCC 29213) over a period 
of 24 hour exposure to the respective MBC value (µg/mL) of H-OOWW-NH2, C12-OOWW-
NH2 and Maximin-4 based on five replicates. 
Key: 
 
NS: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant 
difference between Log10CFU/mL of peptide and the positive control at the same time point 
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Fig. 3 Log10 planktonic viable counts (Log10CFU/mL) of MRSA (ATCC 43300) over a period 
of 24 hour exposure to the respective MBC value (µg/mL) of H-OOWW-NH2, C12-OOWW-
NH2 and Maximin-4 based on five replicates. 
Key: 
 
NS: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant 
difference between Log10CFU/mL of peptide and the positive control at the same time point 
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Fig. 4 Log10 planktonic viable counts (Log10CFU/mL) of Pseudomonas aeruginosa (PAO1) 
over a period of 24 hour exposure to the respective MBC value (µg/mL) of H-OOWW-NH2, 
C12-OOWW-NH2 and Maximin-4 based on five replicates. 
Key: 
 
NS: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant 
difference between Log10CFU/mL of peptide and the positive control at the same time point 
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Fig. 5 Log10 planktonic viable counts (Log10CFU/mL) of E.coli (NCTC 8196) over a period of 
24 hour exposure to the respective MBC value (µg/mL) of H-OOWW-NH2, C12-OOWW-NH2 
and Maximin-4 based on five replicates. 
Key: 
 
NS: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant 
difference between Log10CFU/mL of peptide and the positive control at the same time point 
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Fig. 6  Log10 planktonic viable counts (Log10CFU/mL) of C.tropicalis (NCTC 7393) over a 
period of 24 hour exposure to the respective MFC value (µg/mL) of H-OOWW-NH2, C12-
OOWW-NH2 and Maximin-4 based on five replicates. 
Key: 
 
NS: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant 
difference between Log10CFU/mL of peptide and the positive control at the same time point 
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Fig. 7 Log10 biofilm viable counts (Log10CFU/peg) of MRSE (ATCC 35984) over a period of 24 
hour exposure to the respective MBEC value (µg/mL) of H-OOWW-NH2, C12-OOWW-NH2 
and Maximin-4 based on five replicates. C12-OOWW-NH2 was also tested at 200µg/mL as a 
relative comparator to the MBEC for ultrashort lipopeptides. 
Key: 
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NS: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant 
difference between Log10CFU/mL of peptide and the positive control at the same time point 
 
Fig. 8 Log10 biofilm viable counts (Log10CFU/peg) of S.aureus (ATCC 29213) over a period of 
24 hour exposure to the respective MBEC value (µg/mL) of H-OOWW-NH2, C12-OOWW-NH2 
and Maximin-4 based on five replicates. C12-OOWW-NH2 was also tested at 200µg/mL as a 
relative comparator to the MBEC for ultrashort lipopeptides. 
Key: 
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NS: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant 
difference between Log10CFU/mL of peptide and the positive control at the same time point 
 
 
Fig. 9 Log10 biofilm viable counts (Log10CFU/peg) of MRSA (ATCC 43300) over a period of 
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24 hour exposure to the respective MBEC value (µg/mL) of H-OOWW-NH2, C12-OOWW-NH2 
and Maximin-4 based on five replicates. C12-OOWW-NH2 was also tested at 200µg/mL as a 
relative comparator to the MBEC for ultrashort lipopeptides. 
Key: 
 
NS: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant 
difference between Log10CFU/mL of peptide and the positive control at the same time point 
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Fig. 10 Log10 biofilm viable counts (Log10CFU/peg) of E.coli (NCTC 8196) over a period of 24 
hour exposure to the respective MBEC value (µg/mL) of C12-OOWW-NH2 based on five 
replicates. C12-OOWW-NH2 was also tested at 200µg/mL as a relative comparator to the MBEC 
for ultrashort lipopeptides. 
Key: 
 
NS: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant 
difference between Log10CFU/mL of peptide and the positive control at the same time point 
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Fig. 11. Log10 biofilm viable counts (Log10CFU/peg) of C.tropicalis (NCTC 7393) over a period 
of 24 hour exposure to the respective MBEC value (µg/mL) of C12-OOWW-NH2 based on five 
replicates. C12-OOWW-NH2 was also tested at 200µg/mL as a relative comparator to the MBEC 
for ultrashort lipopeptides. 
Key: 
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NS: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant 
difference between Log10CFU/mL of peptide and the positive control at the same time point 
References 
1. Zasloff M. (2002) Antimicrobial peptides of multicellular organisms. Nature; 24:415:389-395.  
2. Elsbach P. What is the real role of antimicrobial polypeptides that can mediate several other 
inflammatory responses? (2003) J Clin Invest; 111:1643-1645.  
3. Rosenfeld Y., Sahl H.G., Shai Y. (2008) Parameters involved in antimicrobial and endotoxin 
detoxification activities of antimicrobial peptides. Biochemistry; 17:6468-6478.  
4. Yeaman M.R., Yount N.Y.  (2003) Mechanisms of antimicrobial peptide action and resistance. 
Pharmacol Rev;55:27-55.  
5. Brogden K.A. (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? 
Nat Rev Microbiol;3:238-250.  
6. Conlon J.M., Al-Ghaferi N., Abraham B., Leprince J. (2007) Strategies for transformation of 
naturally-occurring amphibian antimicrobial peptides into therapeutically valuable anti-infective 
agents. Methods;42:349-357.  
7. Lai R, Zheng Y.T., Shen J.H., Liu G.J., Liu H., Lee W.H., Tang S.Z., Zhang Y. (2002) 
Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima. 
Peptides;23:427-435.  
8. Lohan S., Cameotra S.S., Bisht G.S. (2013) Systematic study of non-natural short cationic 
lipopeptides as novel broad-spectrum antimicrobial agents. Chem Biol Drug Des;82:557-566.  
9. Laverty G., Gorman S.P., Gilmore B.F. (2011) The potential of antimicrobial peptides as 
biocides. Int J Mol Sci;12:6566-6596.  
10. Makovitzki A., Avrahami D., Shai Y. (2006) Ultrashort antibacterial and antifungal 
lipopeptides. Proc Natl Acad Sci U S A;103:15997-16002.  
11. De Lucca A.J., Walsh T.J. (1999) Antifungal peptides: novel therapeutic compounds against 
emerging pathogens. Antimicrob Agents Chemother;43:1-11.  
12. Bisht G.S., Rawat D.S., Kumar A., Kumar R., Pasha S. (2007) Antimicrobial activity of 
rationally designed amino terminal modified peptides. Bioorg Med Chem Lett;17:4343-4346.  
13. Laverty G., McLaughlin M., Shaw C., Gorman S.P., Gilmore B.F. (2010) Antimicrobial 
activity of short, synthetic cationic lipopeptides. Chem Biol Drug Des;75:563-569.  
 
  
25 
 
14. Laverty G., Gorman S.P., Gilmore B.F. (2012) Antimicrobial peptide incorporated poly(2-
hydroxyethyl methacrylate) hydrogels for the prevention of Staphylococcus epidermidis-
associated biomaterial infections. J Biomed Mater Res A;100:1803-1814.  
15. McKenna M. (2013) Antibiotic resistance: the last resort. Nature;499:394-396.  
16. Stewart P.S. Mechanisms of antibiotic resistance in bacterial biofilms. (2002) Int J Med 
Microbiol;292:107-113.  
17. Davies D. Understanding biofilm resistance to antibacterial agents. (2003) Nat Rev Drug 
Discov;2:114-122.  
18. Booth S.C., George I.F., Zannoni D., Cappelletti M., Duggan G.E., Ceri H, Turner R.J. 
(2013) Effect of aluminium and copper on biofilm development of Pseudomonas 
pseudoalcaligenes KF707 and P. fluorescens as a function of different media compositions. 
Metallomics;5:723-735.  
19. Barry A.L., Craig W.A., Nadler H., Reller L.B., Sanders C.C., Swenson J.M. (1999) Methods 
for determining bactericidal activity of antimicrobial agents; approved guidelines. CLSI 
Guidelines M26-A:1-29.  
20. Stratton C.W., Liu C., Ratner H.B., Weeks L.S. (1987) Bactericidal activity of deptomycin 
(LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against 
enterococci as determined by kill-kinetic studies. Antimicrob Agents Chemother;31:1014-1016.  
21. Carson L., Chau P.K.W., Earle M.J., Gilea M.A., Gilmore B.F., Gorman S.P., McCann M., 
Seddon K.R. (2009) Antibiofilm activities of 1-alkyl-3-methylimidazolium chloride ionic 
liquids. Green Chem;11:492-497.  
22. Smith K., Perez A., Ramage G., Gemmell C.G., Lang S. (2009) Comparison of biofilm-
associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus 
biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J 
Antimicrob Agents;33:374-378.  
23. Coates A.R., Hu Y. (2008) Targeting non-multiplying organisms as a way to develop novel 
antimicrobials. Trends Pharmacol Sci;29:143-150.  
24. Billings N., Millan M., Caldara M., Rusconi R., Tarasova Y., Stocker R., Ribbeck K. (2013) 
The extracellular matrix Component Psl provides fast-acting antibiotic defense in Pseudomonas 
aeruginosa biofilms. PLoS Pathog;9:e1003526.  
25. An M.M., Shen H., Zhang J.D., Xu G.T., Jiang Y.Y. (2013) Linezolid versus vancomycin for 
meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled 
trials. Int J Antimicrob Agents;41:426-433.  
 
  
26 
 
26. Shai Y. (2002) Mode of action of membrane active antimicrobial peptides. 
Biopolymers;66:236-248.  
27. Neuhaus F.C., Baddiley J. (2003) A continuum of anionic charge: structures and functions of 
D-alanyl-teichoic acids in gram-positive bacteria. Microbiol Mol Biol Rev;67:686-723.  
28. Muhle S.A., Tam J.P. (2001) Design of Gram-negative selective antimicrobial peptides. 
Biochemistry;40:5777-5785.  
29. Noiri Y., Okami Y., Narimatsu M., Takahashi Y., Kawahara T., Ebisu S. (2003) Effects of 
chlorhexidine, minocycline, and metronidazole on Porphyromonas gingivalis strain 381 in 
biofilms. J Periodontol;74:1647-1651.  
30. Chen H.D., Groisman E.A. (2013) The biology of the PmrA/PmrB two-component system: 
the major regulator of lipopolysaccharide modifications. Annu Rev Microbiol;67:83-112.  
31. Giacometti A., Cirioni O., Barchiesi F., Fortuna M., Scalise G. (1999) In-vitro activity of 
cationic peptides alone and in combination with clinically used antimicrobial agents against 
Pseudomonas aeruginosa. J Antimicrob Chemother;44:641-645.  
32. Giacometti A., Cirioni O., Del Prete M.S., Paggi A.M., D'Errico M.M., Scalise G. (2000) 
Combination studies between polycationic peptides and clinically used antibiotics against Gram-
positive and Gram-negative bacteria. Peptides;21:1155-1160.  
33. Kumar M., Chaturvedi A.K., Kavishwar A., Shukla P.K., Kesarwani A.P., Kundu B. (2005) 
Identification of a novel antifungal nonapeptide generated by combinatorial approach. Int J 
Antimicrob Agents;25:313-320.  
34. Herrmann G., Yang L., Wu H., Song Z., Wang H., Hoiby N., Ulrich M., Molin S., 
Riethmüller J., Döring G. (2010 ) Colistin-tobramycin combinations are superior to monotherapy 
concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis;202:1585-1592.  
 
